Market Cap (In GBp)
2.11 Million
Revenue (In GBp)
-
Net Income (In GBp)
-572.97 Thousand
Avg. Volume
37.99 Million
- Currency
- GBp
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.04-0.44
- PE
- -
- EPS
- -
- Beta Value
- 0.999
- ISIN
- GB00BYW79Y38
- CUSIP
- G6682B100
- CIK
- -
- Shares
- 1695710000.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Daniel John Gooding
- Employee Count
- -
- Website
- https://www.nuformix.com
- Ipo Date
- 2015-12-17
- Details
- Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
More Stocks
-
NS6Belships ASA
NS6
-
603733Xianhe Co.,Ltd.
603733
-
EG
-
600982Ningbo Energy Group Co.,Ltd.
600982
-
GLOHGlow Holdings, Inc.
GLOH
-
5250
-
ALARFAdeunis Société anonyme
ALARF
-
MSF